CADTH Canadian Drug Expert Committee recommendation: Lumacaftor/Ivacaftor (Orkambi -- Vertex Pharmaceuticals (Canada) Incorporated) indication : cystic fibrosis, F508del-cystic fibrosis transmembrane conductance regulator gene mutation in patients aged six years and older
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, October, 2018
|
Edition: | Version 1.0 |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Physical Description: | 1 PDF file (16 pages) |
---|